ContraFect
28 Wells Avenue, Third Floor
Yonkers, NY 10701
United States
Tel: 914-207-2300
Website: http://www.contrafect.com/
140 articles about ContraFect
-
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract BookAbstracts highlight the advancement of three new antibacterial modalities: novel native lysins, engineered lysins and amurin peptides
5/11/2020
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the publication of four abstracts in the 30th European Congress of Clinical Microbiology and Infectious Diseases abstract book.
-
ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference
4/21/2020
ContraFect Corporation announced that Roger J. Pomerantz, M.D., F.A.C.P., President, Chief Executive Officer, and Chairman of ContraFect, will deliver the keynote address to open Maxim’s Infectious Disease Virtual Conference to be held on May 5, 2020.
-
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
3/18/2020
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced financial results for the fourth quarter and full year ended December 31, 2019.
-
ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development
3/4/2020
ContraFect Corporation announced that Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer, will serve as a panel member at the invitation of the Food and Drug Administration and provide industry perspective at the FDA’s public workshop entitled “Advancing Animal Models for Antibacterial Drug Development”.
-
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
2/24/2020
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia
-
ContraFect Announces One-for-Ten Reverse Stock Split
2/4/2020
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced a one-for-ten reverse stock split of its shares of common stock.
-
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
2/3/2020
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Jane E. Ambler, Ph.D. has been appointed as Vice President of Clinical Microbiology.
-
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
1/27/2020
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including Lysins and Amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has been granted two oral presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 18-21, 2020, in Paris, France.
-
ContraFect to Present at 2020 ASM Biothreats
1/22/2020
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research has been invited to discuss the potential role of DLAs
-
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
1/13/2020
ContraFect Corporation announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections under Temporary Authorizations for Use from the French National Agency for Medicines and Health Products Safety in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France.
-
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
1/10/2020
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia,
-
ContraFect to Present at Biotech Showcase 2020
1/6/2020
ContraFect Corporation announced that Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect will present an update on the recently initiated pivotal Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis, and a general corporate overview at the Biotech Showcase on Monday, January 13, 2020, at 2:30 PM PT in San Francisco, CA..
-
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
12/20/2019
Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia
-
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
12/18/2019
Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa
-
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock
12/17/2019
The gross proceeds from the offering will be approximately $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect.
-
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
12/10/2019
ContraFect Corporation announced the pricing of its underwritten public offering of 37,150,000 shares of its common stock at a public offering price of $0.27 per share.
-
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.
12/9/2019
The public offering is subject to market conditions and the private placement is contingent upon the closing of the public offering, and there can be no assurance as to whether or when the public offering and private placement may be completed, or the actual size or terms of the public offering and private placement.
-
ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference
11/29/2019
ContraFect Corporation announced that Roger J. Pomerantz, MD, President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019, at 12:00 PM ET in New York City.
-
ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update
11/12/2019
ContraFect Corporation announced financial results for the third quarter ended September 30, 2019.
-
ContraFect to Present at the World Anti-Microbial Resistance Congress 2019
11/5/2019
ContraFect Corporation announced that Cara Cassino, MD, ContraFect’s Chief Medical Officer and Executive Vice President of Research & Development was invited to discuss the exebacase superiority design trial at the World Anti-Microbial Resistance Congress 2019, to be held from November 7-8, 2019, in Washington, D.C.